Retrospective analysis of rosiglitazone and macular oedema in patients with type 2 diabetes mellitus

Clinical Drug Investigation

Volumn 28, Issue 5, 2008, Pages 327-332

  Tatti, Patrizio ^a,c   Arrigoni, Franco ^a   Longobardi, Adriano ^a   Costanza, Flavia ^a   Di Blasi, Patrizia ^b   Merante, Domenico ^b  

^a Marino Hospital Rome   (Italy)

^b GSK   (Italy)

^c UCO di Endocrinologia e Diabetologia   (Italy)

Author keywords

Diabetes mellitus; Retinal oedema; Rosiglitazone, adverse reactions; Type 2 diabetes mellitus

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; INSULIN; IRBESARTAN; LOSARTAN; METFORMIN; RAMIPRIL; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; AUTONOMIC NEUROPATHY; COLOR BLINDNESS; COLOR VISION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; DYSLIPIDEMIA; EYE FUNDUS; FEMALE; HUMAN; HYPERPNEA; HYPERTENSION; INFORMED CONSENT; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RETINA MACULA EDEMA; RETROSPECTIVE STUDY; VISUAL ACUITY; VISUAL DISORDER; VISUAL FIELD;

EID: 42049113031     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828050-00006     Document Type: Article

References (16)

1. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-8
2. Goldstein BJ. Differentiating members of the thiazolidinedione class: a focus on efficacy. Diabetes Metabol Res Rev 2002; 18: S16-22
3. Wooltorton E. Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. CMAJ 2002; 166 (2): 219
4. Scheen A. Combined thiazolidinedione-insulin therapy: should we be concerned about safety? Drug Saf 2004; 27 (12): 841-56
5. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004 Jan; 27 (1): 256-63
6. Canadian Diabetes Association. 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003; 27 Suppl. 2: S1-152
7. Harby K. Glitazone use may be associated with macular edema in diabetes [online]. Available from URL: http://www.medscape.com/viewarticle/464732. [Accessed 2004 July 7]
8. Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol 2005; 123: 1273-5
9. Kendall C, Wooltorton E. Rosiglitazone (Avandia) and macular edema. CMAJ 2006 Feb 28; 174 (5): 623
10. Porta M, Bandello F. Diabetic retinopathy: a clinical update. Diabetologia 2002; 45: 1617-34
11. European Medicines Agency press release. Committee for Medicinal Products for Human Use: 2005 Dec 11-14 [online]. Available from URL: http://www.emea.eu.int/pdfs/human/press/pr/42148405en.pdf [Accessed 2008 Apr 8]
12. Nota informativa importante su Rosiglitazone from AIFA (2006 Jan 19) [online]. Available from URL: http://www.aifa.gov.it/ wscs_render_attachment_by_id/111.6043. 11380328864053963.pdf?id=111.6050. 1138032886728 [Accessed 2008 Apr 8]
13. Cavanagh P. The Ishihara test and defects of colour vision. Br J Physiol Opt 1956 Jan; 13 (1): 25-38
14. Wolfe KA, Sadun AA. Threshold Amsler grid testing in diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 1991; 229 (3): 219-23
15. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003; 26: 2653-64
16. Avandia. Summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?.DocumentID = 3200 [Accessed 2008 Apr 8]